[go: up one dir, main page]

IL137510A0 - Compositions comprising viruses and methods for concentrating virus preparations - Google Patents

Compositions comprising viruses and methods for concentrating virus preparations

Info

Publication number
IL137510A0
IL137510A0 IL13751099A IL13751099A IL137510A0 IL 137510 A0 IL137510 A0 IL 137510A0 IL 13751099 A IL13751099 A IL 13751099A IL 13751099 A IL13751099 A IL 13751099A IL 137510 A0 IL137510 A0 IL 137510A0
Authority
IL
Israel
Prior art keywords
viruses
compositions
methods
virus preparations
concentrating virus
Prior art date
Application number
IL13751099A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of IL137510A0 publication Critical patent/IL137510A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL13751099A 1998-02-17 1999-02-12 Compositions comprising viruses and methods for concentrating virus preparations IL137510A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2446298A 1998-02-17 1998-02-17
US7964398A 1998-05-15 1998-05-15
PCT/US1999/001873 WO1999041416A2 (en) 1998-02-17 1999-02-12 Compositions comprising viruses and methods for concentrating virus preparations

Publications (1)

Publication Number Publication Date
IL137510A0 true IL137510A0 (en) 2001-07-24

Family

ID=26698472

Family Applications (2)

Application Number Title Priority Date Filing Date
IL13751099A IL137510A0 (en) 1998-02-17 1999-02-12 Compositions comprising viruses and methods for concentrating virus preparations
IL137510A IL137510A (en) 1998-02-17 2000-07-25 Vaccines for maintaining the stability of adenoviruses

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL137510A IL137510A (en) 1998-02-17 2000-07-25 Vaccines for maintaining the stability of adenoviruses

Country Status (24)

Country Link
EP (4) EP1526174B1 (pt)
JP (3) JP4358434B2 (pt)
KR (5) KR101018992B1 (pt)
CN (2) CN101164623B (pt)
AR (3) AR020054A1 (pt)
AT (3) ATE478945T1 (pt)
AU (1) AU757976B2 (pt)
BR (1) BR9908015A (pt)
CA (2) CA2320419C (pt)
CO (1) CO4820440A1 (pt)
DE (3) DE69936948T2 (pt)
DK (1) DK1054955T3 (pt)
ES (2) ES2290613T3 (pt)
HU (1) HU226015B1 (pt)
ID (1) ID28298A (pt)
IL (2) IL137510A0 (pt)
MY (1) MY141641A (pt)
NO (1) NO20004104L (pt)
PE (1) PE20000265A1 (pt)
PL (1) PL197747B1 (pt)
PT (1) PT1054955E (pt)
SK (1) SK11842000A3 (pt)
TW (1) TWI232107B (pt)
WO (1) WO1999041416A2 (pt)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE348155T1 (de) 1996-11-20 2007-01-15 Introgen Therapeutics Inc Ein verbessertes verfahren zur produktion und reinigung von adenoviralen vektoren
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
WO2000029024A1 (en) * 1998-11-16 2000-05-25 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US7456009B2 (en) 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
CA2399321C (en) 2000-03-07 2013-04-30 Robert K. Evans Adenovirus formulations
US20020064860A1 (en) 2000-11-29 2002-05-30 Schering Corporation Method for purifying adenoviruses
WO2002047726A2 (en) * 2000-12-12 2002-06-20 Japan Tobacco Inc. Pharmaceutical composition containing an active with a hemolytic action and a surfactant
WO2003049764A1 (en) 2001-12-12 2003-06-19 Fh Faulding & Co Limited Composition for viral preservation
US20030153065A1 (en) * 2002-01-14 2003-08-14 Genvec, Inc. Composition and method for maintaining non-enveloped viral vectors
EP1465664A1 (en) * 2002-01-18 2004-10-13 Schering Aktiengesellschaft Stabilized formulations of adenovirus
EP1780269B1 (en) 2004-02-23 2009-07-08 Crucell Holland B.V. Virus purification methods
JP2008518632A (ja) 2004-11-03 2008-06-05 イントロゲン セラピューティックス， インコーポレイテッド アデノウイルスベクターの製造および精製のための新規方法
JP4621743B2 (ja) 2004-12-13 2011-01-26 カンジ，インコーポレイテッド 複製欠損アデノウイルスの産生のための細胞株
DK1869171T4 (en) 2005-04-11 2016-01-18 Crucell Holland Bv Virus cleaning using ultrafiltration
CN1961961B (zh) * 2005-11-11 2010-05-26 深圳市源兴生物医药科技有限公司 一种药物制剂及其制备方法
ATE497010T1 (de) 2005-12-12 2011-02-15 Canji Inc Adenovirale expressionsvektoren mit einer expressionskassette im e1-bereich und einer inaktivierten e2b-polymerase
PL2007883T3 (pl) * 2006-04-20 2012-07-31 Wyeth Llc Sposób oczyszczania do izolacji oczyszczonego wirusa pęcherzykowatego zapalenia jamy ustnej z hodowli komórkowej
WO2010060719A1 (en) 2008-11-03 2010-06-03 Crucell Holland B.V. Method for the production of adenoviral vectors
SG10202109219SA (en) 2009-05-02 2021-10-28 Genzyme Corp Gene therapy for neurodegenerative disorders
DK2536829T3 (en) 2010-02-15 2016-07-04 Crucell Holland Bv A process for the production of Ad26-adenovirus vectors
CN103118702A (zh) 2010-09-20 2013-05-22 克鲁塞尔荷兰公司 活动性结核病的治疗性接种
AU2011310838B2 (en) 2010-09-27 2015-11-05 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
EA201390810A1 (ru) * 2010-12-02 2013-09-30 Онколитикс Байотек Инк. Жидкие вирусные составы
EA201390812A1 (ru) 2010-12-02 2013-11-29 Онколитикс Байотек Инк. Лиофилизированные вирусные составы
DK2702147T3 (da) * 2011-04-29 2020-09-28 Oncolytics Biotech Inc Fremgangsmåder til oprensning af vira ved hjælp af gelpermeationskromatografi
CA2864956C (en) 2012-03-12 2021-11-09 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
US9119813B2 (en) 2012-03-22 2015-09-01 Crucell Holland B.V. Vaccine against RSV
KR102023791B1 (ko) 2012-03-22 2019-09-23 얀센 백신스 앤드 프리벤션 비.브이. Rsv에 대한 백신
US10899800B2 (en) 2013-04-25 2021-01-26 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
PE20160045A1 (es) 2013-06-17 2016-02-18 Crucell Holland Bv Polipeptidos f de prefusion del virus sincicial respiratorio (rsv) solubles y estabilizados
WO2015183180A1 (en) * 2014-05-28 2015-12-03 Agency For Science, Technology And Research Virus reduction method
AU2016249798B2 (en) 2015-04-14 2022-05-26 Janssen Vaccines And Prevention B.V. Recombinant adenovirus expressing two transgenes with a bidirectional promoter
KR102638978B1 (ko) 2015-07-07 2024-02-22 얀센 백신스 앤드 프리벤션 비.브이. Rsv에 대한 백신
KR20180026734A (ko) 2015-07-07 2018-03-13 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 가용성 융합-전 rsv f 폴리펩티드
PH12022552125A1 (en) 2016-04-05 2023-04-12 Janssen Vaccines & Prevention Bv Stabilized soluble pre-fusion rsv f proteins
EA201892250A1 (ru) 2016-04-05 2019-03-29 Янссен Вэксинс Энд Превеншн Б.В. Вакцина против rsv
EA039124B1 (ru) 2016-05-30 2021-12-08 Янссен Вэксинс Энд Превеншн Б.В. Стабилизированные f-белки rsv до слияния
MX393584B (es) 2016-06-20 2025-03-21 Janssen Vaccines & Prevention Bv Promotor bidireccional potente y equilibrado.
EP3484506A1 (en) 2016-07-14 2019-05-22 Janssen Vaccines & Prevention B.V. Hpv vaccines
WO2018210871A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
AU2018267971A1 (en) 2017-05-17 2019-11-07 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against RSV infection
WO2019021305A1 (en) * 2017-07-24 2019-01-31 Ella Foundation VACCINE AGAINST FOOT AND MOUTH DISEASE
JP2020533367A (ja) 2017-09-15 2020-11-19 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． Ｒｓｖに対する免疫の安全な誘導方法
MX2021005607A (es) 2018-11-13 2021-06-30 Janssen Vaccines & Prevention Bv Proteinas f de prefusion del vrs estabilizadas.
CN114173827B (zh) * 2019-06-28 2025-01-28 武田药品工业株式会社 腺相关病毒纯化方法
EP4097122A4 (en) 2020-01-31 2024-07-17 Beth Israel Deaconess Medical Center, Inc. COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING CORONAVIRUS INFECTION - SARS-COV-2 VACCINES
WO2021186246A1 (en) * 2020-03-19 2021-09-23 Trizell Ltd. Temperature-responsive virus storage system
EP4294436A1 (en) 2021-02-19 2023-12-27 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv fb fantigens
WO2023020939A1 (en) 2021-08-17 2023-02-23 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
CN115989321A (zh) * 2021-08-17 2023-04-18 上海行深生物科技有限公司 病毒制剂、用于配制病毒制剂的溶液及其用途
WO2023111725A1 (en) 2021-12-14 2023-06-22 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE299213C (pt) *
US4147772A (en) * 1976-02-03 1979-04-03 Merck & Co., Inc. Vaccine stabilizer
GB1575155A (en) * 1978-04-11 1980-09-17 Merck & Co Inc Vaccine stabilizer
BE866330A (fr) * 1978-04-25 1978-10-25 Merck & Co Inc Procede de fabrication d'un agent de stabilisation de vaccin
US5532220A (en) 1987-08-31 1996-07-02 The Regents Of The University Of California Genetic mechanisms of tumor suppression
DD299213A7 (de) * 1988-05-04 1992-04-09 Saechsische Landesgewerbefoerderungsgesellschaft M.B.H.,De Verfahren zur stabilisierung eines lebendvirusimpfstoffes gegen temperatureinwirkung
DD295927A5 (de) * 1988-05-06 1991-11-14 Saechsisches Serumwerk Gmbh Dresden, Immobilisiertes immunologisch aktives reagens
DK0797676T3 (da) 1993-10-25 2006-04-18 Canji Inc Rekombinant adenoviral vektor og fremgangsmåder til anvendelse deraf
KR100368686B1 (ko) * 1994-12-29 2003-12-01 주식회사 엘지생명과학 수크로즈를이용한세포와바이러스의분리방법
FR2742756B1 (fr) * 1995-12-22 1998-04-03 Pasteur Merieux Serums Vacc Stabilisants pour vaccins vivants, vaccins les contenant et procedes pour leur preparation
US5789244A (en) 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems

Also Published As

Publication number Publication date
KR20010072547A (ko) 2001-07-31
ATE478945T1 (de) 2010-09-15
DE69933433T2 (de) 2007-08-23
DE69933433D1 (de) 2006-11-16
CA2320419A1 (en) 1999-08-19
HUP0100670A2 (hu) 2001-06-28
EP1526173A3 (en) 2005-08-10
MY141641A (en) 2010-05-31
PL197747B1 (pl) 2008-04-30
EP1526174A2 (en) 2005-04-27
CN101164623A (zh) 2008-04-23
CN101164623B (zh) 2012-11-14
KR100918187B1 (ko) 2009-09-22
ES2290613T3 (es) 2008-02-16
CN100374551C (zh) 2008-03-12
EP1526174A3 (en) 2005-08-31
AR020054A1 (es) 2002-04-10
TWI232107B (en) 2005-05-11
ES2272053T3 (es) 2007-04-16
KR100912362B1 (ko) 2009-08-19
HK1028416A1 (en) 2001-02-16
JP2006166925A (ja) 2006-06-29
EP1054955A2 (en) 2000-11-29
EP1741777A1 (en) 2007-01-10
EP1526174B1 (en) 2007-08-22
KR20090127947A (ko) 2009-12-14
HK1073481A1 (en) 2005-10-07
ID28298A (id) 2001-05-10
KR20080065614A (ko) 2008-07-14
KR20090038927A (ko) 2009-04-21
DK1054955T3 (da) 2007-01-15
DE69936948T2 (de) 2008-05-15
PE20000265A1 (es) 2000-04-25
CN1297478A (zh) 2001-05-30
KR100991683B1 (ko) 2010-11-04
KR20080065615A (ko) 2008-07-14
AR063314A2 (es) 2009-01-21
IL137510A (en) 2012-10-31
NO20004104D0 (no) 2000-08-16
PT1054955E (pt) 2007-01-31
HUP0100670A3 (en) 2003-10-28
JP2010213727A (ja) 2010-09-30
HK1097413A1 (en) 2007-06-22
EP1741777B1 (en) 2010-08-25
KR100862169B1 (ko) 2008-10-09
EP1054955B1 (en) 2006-10-04
ATE341614T1 (de) 2006-10-15
KR101018992B1 (ko) 2011-03-07
EP1526173A2 (en) 2005-04-27
JP2002503484A (ja) 2002-02-05
DE69936948D1 (de) 2007-10-04
NO20004104L (no) 2000-10-17
PL342847A1 (en) 2001-07-16
WO1999041416A2 (en) 1999-08-19
AU757976B2 (en) 2003-03-13
CA2723040A1 (en) 1999-08-19
BR9908015A (pt) 2001-04-24
WO1999041416A3 (en) 1999-11-18
ATE371020T1 (de) 2007-09-15
HU226015B1 (en) 2008-02-28
CA2320419C (en) 2011-02-08
AR063315A2 (es) 2009-01-21
JP4358434B2 (ja) 2009-11-04
DE69942708D1 (de) 2010-10-07
EP1526173B1 (en) 2012-11-21
CO4820440A1 (es) 1999-07-28
AU2653899A (en) 1999-08-30
SK11842000A3 (sk) 2001-05-10

Similar Documents

Publication Publication Date Title
IL137510A0 (en) Compositions comprising viruses and methods for concentrating virus preparations
EP1292603B8 (en) Methods and compositions for treating hepatitis c virus
GB2337755B (en) Virus vaccine
AU5285899A (en) Anti hepatitis c virus antibody and uses thereof
HUP0103908A3 (en) Novel infulenza virus vaccine composition
AU2002330154A1 (en) Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
AU4813197A (en) Compositions and methods for treating viral infections
CZ20011341A3 (cs) Pomocné přípravky a vakciny
HUP0104548A3 (en) Hepatitis c inhibitor peptides, process for their preparation, pharmaceutical compositions conprising thereof and their use
AU7501898A (en) Live attenuated virus vaccines for equine encephalitis viruses
AU7261898A (en) Methods for viral inactivation and compositions for use in same
EP1113777A4 (en) NOVEL HEPATITIS C VIRUS PEPTIDES AND USES THEREOF
GB9809666D0 (en) Modified viruses
AU4132096A (en) Compositions and methods for interfering with hepatitis b virus infection
AU8382198A (en) Methods for inactivating enveloped rna virus particles and compositions for use therewith
EP1068362A4 (en) HEPATITIS C VIRUS NS5B COMPOSITIONS AND METHOD FOR THEIR USE
ZA991235B (en) Compositions comprising viruses and methods for concentrating virus preparations.
GB9916651D0 (en) Herbal composition and method of treating viral infection of the liver
GB9925432D0 (en) Virus preparation
GB9702990D0 (en) Virus vaccine
AU4399197A (en) Hepatitis c virus epitope
GB9908224D0 (en) Virus preparations and methods
AU5082698A (en) Heat inactivation of viruses in antibody preparations
AU2003204545A1 (en) Methods and compositions for inactivating viruses
HU0800022D0 (en) Method for concentrating virus preparations